1. Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG;Au;Expert Rev Pharmacoecon Outcomes Res,2010
2. Health-related quality of life and cancer clinical trials;Osoba;Ther Adv Med Oncol,2011
3. Haute Autorité de Santé. Évaluation des technologies de santé à la HAS: place de la qualité de vie. HAS; 2018:8. Accessed June 14, 2023. 〈https://www.has-sante.fr/upload/docs/application/pdf/2018-10/note_de_synthese_place_de_la_qualite_de_vie.pdf〉
4. Transparency Committee. TYVERB (lapatinib) - Opinions on drugs - Posted on Sep 15 2009 - Inclusion on the list of medicines approved for use by hospitals for the extension of indication: “TAXOTERE (docetaxel) in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.” Haute Autorité de Santé (HAS); 2008. https://www.has-sante.fr/jcms/c_684109/en/tyverb-lapatinib/-lapatinib-ditosilate-de-monohydrate
5. Transparency Committee. NAVELBINE (vinorelbine (tartrate de)) (breast) - Opinions on drugs - Posted on May 17 2011 - Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals in the extension of indication “combination chemotherapy in metastatic breast cancer.” Haute Autorité de Santé (HAS); 2009. 〈https://www.has-sante.fr/jcms/c_798071/en/navelbine-sein〉